bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2025-2031

  Charpin, Colette ^a   Garcia, Stéphane ^a   Bonnier, Pascal ^a   Martini, François ^a   Andrac, Lucile ^a   Horschowski, Nicole ^a   Lavaut, Marie Noëlle ^a   Allasia, Claude ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIDASE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOANALYSIS; AUTOANALYZER; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DEVICE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0031799122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2025     Document Type: Article

References (45)

1. Wyllie AH, Morris RG, Smith AL, et al: Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 153:313-319, 1987
2. Wyllie AH: Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205-208, 1993
3. Hockenbery D, Nunez G, Milliman C, et al: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:34-37, 1990
4. Reed JC: bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
5. Hockenbery DM: bcl-2, a novel regulator of cell death. BioEssays 17:631-638, 1995
6. Holzman D: Apoptosis provides new targets for chemotherapy. J Natl Cancer Inst 88:1098-1100, 1996
7. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280, 1990
8. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glycocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992
9. Miyashita T, Reed JC: bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993
10. Alnemri ES, Fernandez TF, Haldar S, et al: Involvement of bcl-2 in glucocorticoid-induced apoptosis of human pre-B leukemia. Cancer Res 52:491-495, 1992
11. Fisher TC, Milner AE, Gregory CD, et al: bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53:3321-3327, 1993
12. Vaux D, Cory S, Adams J: bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988
13. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
14. Lipponen P, Pietillaïnen T, Kosma VM, et al: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177:49-55, 1995
15. Hellemans P, Van Dam PA, Weyler J, et al: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72:354-360, 1995
16. Silvestrini R, Benini E, Veneroni S, et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
17. Johnston SRD, MacLennan KA, Sacks NPM, et al: Modulation of bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A: 1662-1669, 1994
18. Gee JMW, Robertson JFR, Ellis IO, et al: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628, 1994
19. Teixeira C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907, 1995
20. Nathan B, Gusterson B, Jadayel D, et al: Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5:409-414, 1994
21. Charpin C, Garcia S, Bouvier C, et al: Automated and quantitative immunocytochemical assays of bcl-2 protein in breast carcinomas. Br J Cancer (in press)
22. Charpin C, Vielh P, Duffaud F, et al: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86:1539-1545, 1994
23. Charpin C, Devictor B, Bergeret D, et al: CD 31 quantitative immunohistochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Path 103:443-448, 1995
24. Galea MH, Blarney RW, Elston CE, et al: The Nottingham prognostic index in primary breast cancer. Br Cancer Res Treat 22:207-219, 1992
25. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci 83:5214-5218, 1986
26. Clearly ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t (14:18) translocation. Cell 47:19-28, 1986
27. Grogan TM, Casey TT, Miller PC, et al: Automation of immunohistochemistry. Adv Path Lab Med 6:253-283, 1993
28. Galaktionov K, Lee AK, Eckstein J, et al: CDC25 phosphatases as potential human oncogenes. Science 269:1575-1577, 1995
29. Santavicca M, Noel A, Chenard MP, et al: Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry. Int J Cancer 64:336-341, 1995
30. Charpin C, Andrac L, Vacheret H, et al: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma: A correlation of immunodetection in tissues sections and morphological data and estrogen and progesterone receptor immunocytochemical assays. Cancer Res 48:4368-4374, 1988
31. Esteban JM, Cul AHN, Mehta P, et al: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 102:158-162, 1994
32. Santisteban MS, Brugal G: Image analysis of in situ cell cycle related changes of PCNA and Ki-67 proliferation antigen expression. Cell Prolif 27:435-453, 1994
33. Altman DG, Lausen B, Sauerberi W, et al: Dangers of using "optimal" cutpoint in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
34. Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
35. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes regulators of cell death. Blood 80:879-886, 1992
36. Siegel RM, Katsumata M, Miyashita T, et al: Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci 89:7003-7007, 1992
37. Krajewski S, Tanaka S, Takayama S, et al: Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714, 1993
38. Kernohan NM, Cox LS: Regulation of apoptosis by bcl-2 and its related proteins: Immunochemical challenges and therapeutic implications. J Pathol 179:1-3, 1996
39. Kandouz M, Compel A, Therwath A: bcl-2 proto-oncogene, apoptosis and oncogenesis: An overview. Int J Oncol 9:563-566, 1996
40. Oltvai ZN, Milliman CL, Korsmeyer SJ: bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74:609-619, 1993
41. Yang E, Zha J, Jock l J, et al: bad, a heterodimeric partner for bcl-xL and bcl-2 displaces ax and promotes cell death. Cell 80:285-921, 1995
42. Chittenden T, Harrington EA, O'Connor R, et al: Induction of apoptosis by the bcl-2 homologue bak. Nature 374:733-736, 1995
43. Takayama S, Sato T, Krajewski S, et al: Cloning and functional analysis of BAG-1: A novel bcl-2 binding protein with anti-cell death activity. Cell 80:279-284, 1995
44. Gottschalk AR, Boise LH, Thompson CB, et al: Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci 91:7350-7354, 1994
45. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994